{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:53:23Z","timestamp":1792612403623,"version":"4.5.0"},"reference-count":121,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.molmed.2019.02.001","type":"journal-article","created":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T17:01:11Z","timestamp":1552064471000},"page":"395-411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["The Role of Epigenetic Modifications in Systemic Sclerosis: A Druggable Target"],"prefix":"10.1016","volume":"25","author":[{"given":"John","family":"Henderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2019.02.001_bib0005","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/1529-0131(200106)44:6<1359::AID-ART228>3.0.CO;2-S","article-title":"Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts","volume":"44","author":"Arnett","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2019.02.001_bib0010","doi-asserted-by":"crossref","first-page":"A311","DOI":"10.1016\/j.autrev.2009.11.003","article-title":"Geoepidemiology of systemic sclerosis","volume":"9","author":"Ranque","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.molmed.2019.02.001_bib0015","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/BOR.0b013e32834ff2e8","article-title":"Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers","volume":"24","author":"Barnes","year":"2012","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0020","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0889-857X(03)00022-X","article-title":"Scleroderma epidemiology","volume":"29","author":"Mayes","year":"2003","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"10.1016\/j.molmed.2019.02.001_bib0025","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1126\/science.187.4173.226","article-title":"DNA modification mechanisms and gene activity during development","volume":"187","author":"Holliday","year":"1975","journal-title":"Science"},{"key":"10.1016\/j.molmed.2019.02.001_bib0030","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrg.2017.80","article-title":"The DNA methyltransferase family: a versatile toolkit for epigenetic regulation","volume":"19","author":"Lyko","year":"2017","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.molmed.2019.02.001_bib0035","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1136\/annrheumdis-2014-205303","article-title":"Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies","volume":"74","author":"Altorok","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2019.02.001_bib0040","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1002\/art.34424","article-title":"Wnt\/\u03b2-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells","volume":"64","author":"Wei","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2019.02.001_bib0045","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/annrheumdis-2012-203194","article-title":"The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis","volume":"73","author":"Dees","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2019.02.001_bib0050","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1755-1536-7-14","article-title":"Secreted frizzled related proteins inhibit fibrosis in vitro but appear redundant in vivo","volume":"7","author":"De Langhe","year":"2014","journal-title":"Fibrogenesis Tissue Repair"},{"key":"10.1016\/j.molmed.2019.02.001_bib0055","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/exd.12767","article-title":"Global DNA hypomethylation and hypoxia-induced expression of the ten eleven translocation (TET) family, TET1, in scleroderma fibroblasts","volume":"24","author":"Hattori","year":"2015","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0060","article-title":"Methyl cap binding protein 2: a key epigenetic protein in systemic sclerosis","author":"Henderson","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.molmed.2019.02.001_bib0065","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1136\/annrheumdis-2012-202742","article-title":"New insight on the Xq28 association with systemic sclerosis","volume":"72","author":"Carmona","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2019.02.001_bib0070","doi-asserted-by":"crossref","first-page":"25066","DOI":"10.1038\/srep25066","article-title":"IL-13 mediates collagen deposition via STAT6 and microRNA-135b: a role for epigenetics","volume":"6","author":"O\u2019Reilly","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2019.02.001_bib0075","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/annrheumdis-2017-212265","article-title":"Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis","volume":"77","author":"Zhang","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2019.02.001_bib0080","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.3899\/jrheum.100398","article-title":"High DNA oxidative damage in systemic sclerosis","volume":"37","author":"Avouac","year":"2010","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0085","doi-asserted-by":"crossref","first-page":"ra84","DOI":"10.1126\/scisignal.2004592","article-title":"Oxidative DNA damage induces the ATM-mediated transcriptional suppression of the Wnt inhibitor WIF-1 in systemic sclerosis and fibrosis","volume":"7","author":"Svegliati","year":"2014","journal-title":"Sci. Signal."},{"key":"10.1016\/j.molmed.2019.02.001_bib0090","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.jid.2017.12.003","article-title":"Genome-wide DNA methylation analysis in systemic sclerosis reveals hypomethylation of IFN-associated genes in CD4(+) and CD8(+) T cells","volume":"138","author":"Ding","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0095","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/03009740902758875","article-title":"Abnormal DNA methylation in CD4+ T cells from patients with systemic lupus erythematosus, systemic sclerosis, and dermatomyositis","volume":"38","author":"Lei","year":"2009","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1868-7083-6-25","article-title":"Hypomethylation and overexpression of ITGAL (CD11a) in CD4(+) T cells in systemic sclerosis","volume":"6","author":"Wang","year":"2014","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.molmed.2019.02.001_bib0105","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/annrheumdis-2017-211501","article-title":"The histone demethylase Jumonji domain-containing protein 3 (JMJD3) regulates fibroblast activation in systemic sclerosis","volume":"77","author":"Bergmann","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2019.02.001_bib0110","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.vph.2012.12.001","article-title":"The Fra-2 transgenic mouse model of systemic sclerosis","volume":"58","author":"Maurer","year":"2013","journal-title":"Vascul. Pharmacol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0115","article-title":"A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth","volume":"4","author":"Wang","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2019.02.001_bib0120","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.yexcr.2017.08.024","article-title":"GSKJ4, an H3K27me3 demethylase inhibitor, effectively suppresses the breast cancer stem cells","volume":"359","author":"Yan","year":"2017","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.molmed.2019.02.001_bib0125","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.molcel.2012.11.006","article-title":"Histone lysine methylation dynamics: establishment, regulation, and biological impact","volume":"48","author":"Black","year":"2012","journal-title":"Mol. Cell."},{"key":"10.1016\/j.molmed.2019.02.001_bib0130","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.12915","article-title":"EZH2 enhances the differentiation of fibroblasts into myofibroblasts in idiopathic pulmonary fibrosis","volume":"4","author":"Xiao","year":"2016","journal-title":"Physiol. Rep."},{"key":"10.1016\/j.molmed.2019.02.001_bib0135","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1111\/jcmm.13153","article-title":"EZH2-mediated repression of Dkk1 promotes hepatic stellate cell activation and hepatic fibrosis","volume":"21","author":"Yang","year":"2017","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.molmed.2019.02.001_bib0140","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/art.39061","article-title":"The histone deacetylase Sirtuin 1 is reduced in systemic sclerosis and abrogates fibrotic responses by targeting transforming growth factor \u03b2 signaling","volume":"67","author":"Wei","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0145","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1681\/ASN.2014090850","article-title":"Inhibition of SET domain\u2013containing lysine methyltransferase 7\/9 ameliorates renal fibrosis","volume":"27","author":"Sasaki","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196844","article-title":"Inhibition of the H3K4 methyltransferase SET7\/9 ameliorates peritoneal fibrosis","volume":"13","author":"Tamura","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2019.02.001_bib0155","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.3892\/ijmm.2012.1150","article-title":"Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of Dnmt1 and upregulation of Fli1","volume":"30","author":"Bujor","year":"2012","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.molmed.2019.02.001_bib0160","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1346-8138.2010.00826.x","article-title":"Ciprofloxacin utility as antifibrotic in the skin of patients with scleroderma","volume":"37","author":"Rub\u00e9n","year":"2010","journal-title":"J. Dermatol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0165","doi-asserted-by":"crossref","first-page":"14910","DOI":"10.1038\/srep14910","article-title":"Methylation-mediated BMPER expression in fibroblast activation in vitro and lung fibrosis in mice in vivo","volume":"5","author":"Huan","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2019.02.001_bib0170","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.3109\/10428194.2013.833333","article-title":"Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia","volume":"55","author":"Walker","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.molmed.2019.02.001_bib0175","first-page":"285","article-title":"Effect of the methylation enzyme inhibitors of 5-aza-2-deoxycytidine on the TGF-beta\/smad signal transduction pathway in human keloid fibroblasts","volume":"29","author":"Zou","year":"2013","journal-title":"Zhonghua Zheng Xing Wai Ke Za Zhi"},{"key":"10.1016\/j.molmed.2019.02.001_bib0180","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2147\/DDDT.S129305","article-title":"Decitabine reverses TGF-beta1-induced epithelial-mesenchymal transition in non-small-cell lung cancer by regulating miR-200\/ZEB axis","volume":"11","author":"Zhang","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.molmed.2019.02.001_bib0185","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.sbi.2018.10.001","article-title":"Beyond histone acetylation\u2014writing and erasing histone acylations","volume":"53","author":"Zhao","year":"2018","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0190","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1165\/rcmb.2016-0192OC","article-title":"Sirtuin1 protects against systemic sclerosis\u2013related pulmonary fibrosis by decreasing proinflammatory and profibrotic processes","volume":"58","author":"Chu","year":"2018","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"1","key":"10.1016\/j.molmed.2019.02.001_bib0195","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/annrheumdis-2014-205740","article-title":"Sirt1 regulates canonical TGF-\u03b2 signalling to control fibroblast activation and tissue fibrosis","volume":"75","author":"Zerr","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molmed.2019.02.001_bib0200","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/nm.3777","article-title":"Orphan nuclear receptor NR4A1 regulates transforming growth factor-\u03b2 signaling and fibrosis","volume":"21","author":"Palumbo-Zerr","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2019.02.001_bib0205","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nature11043","article-title":"SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation","volume":"487","author":"Barber","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2019.02.001_bib0210","doi-asserted-by":"crossref","first-page":"L945","DOI":"10.1152\/ajplung.00473.2016","article-title":"Sirtuin 7 is decreased in pulmonary fibrosis and regulates the fibrotic phenotype of lung fibroblasts","volume":"312","author":"Wyman","year":"2017","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0215","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1183\/09031936.00095113","article-title":"Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice","volume":"43","author":"Sanders","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.molmed.2019.02.001_bib0220","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.intimp.2016.08.008","article-title":"Amelioration of bleomycin-induced lung fibrosis in rats by valproic acid and butyrate: role of nuclear factor kappa-B, proinflammatory cytokines and oxidative stress","volume":"39","author":"Kabel","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0225","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.clml.2018.05.023","article-title":"A phase II trial of bortezomib and vorinostat in mantle cell lymphoma and diffuse large B-cell lymphoma","volume":"18","author":"Yazbeck","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.molmed.2019.02.001_bib0230","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10549-017-4516-x","article-title":"Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer","volume":"167","author":"Luu","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.molmed.2019.02.001_bib0235","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/vop.12331","article-title":"Molecular mechanisms of suberoylanilide hydroxamic acid in the inhibition of TGF-\u03b21-mediated canine corneal fibrosis","volume":"19","author":"Gronkiewicz","year":"2016","journal-title":"Vet. Ophthalmol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0240","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/jid.2012.479","article-title":"p300 is elevated in systemic sclerosis and its expression is positively regulated by TGF-\u03b2: epigenetic feed-forward amplification of fibrosis","volume":"133","author":"Ghosh","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0245","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.bbrc.2017.03.155","article-title":"Activation and overexpression of Sirt1 attenuates lung fibrosis via P300","volume":"486","author":"Zeng","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.molmed.2019.02.001_bib0250","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1080\/15592294.2017.1370173","article-title":"A novel acetyltransferase p300 inhibitor ameliorates hypertension-associated cardio-renal fibrosis","volume":"12","author":"Rai","year":"2017","journal-title":"Epigenetics"},{"key":"10.1016\/j.molmed.2019.02.001_bib0255","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00018-010-0599-9","article-title":"MYST-family histone acetyltransferases: beyond chromatin","volume":"68","author":"Sapountzi","year":"2011","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.molmed.2019.02.001_bib0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164855","article-title":"Depletion of Tip60 from in vivo cardiomyocytes increases myocyte density, followed by cardiac dysfunction, myocyte fallout and lethality","volume":"11","author":"Fisher","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2019.02.001_bib0265","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.repbio.2016.07.002","article-title":"MiRNA-183-5p promotes cell proliferation and inhibits apoptosis in human breast cancer by targeting the PDCD4","volume":"16","author":"Cheng","year":"2016","journal-title":"Reprod. Biol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0270","doi-asserted-by":"crossref","first-page":"39","DOI":"10.7754\/Clin.Lab.2015.150518","article-title":"MicroRNA-153 regulates NRF2 expression and is associated with breast carcinogenesis","volume":"62","author":"Wang","year":"2016","journal-title":"Clin. Lab."},{"key":"10.1016\/j.molmed.2019.02.001_bib0275","doi-asserted-by":"crossref","first-page":"402","DOI":"10.18632\/aging.100042","article-title":"MicroRNAs miR-146a\/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8","volume":"1","author":"Bhaumik","year":"2009","journal-title":"Aging"},{"key":"10.1016\/j.molmed.2019.02.001_bib0280","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.mam.2016.10.001","article-title":"Epigenetics in fibrosis","volume":"54","author":"O\u2019Reilly","year":"2017","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.molmed.2019.02.001_bib0285","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13075-016-0929-x","article-title":"MicroRNAs in fibrosis: opportunities and challenges","volume":"18","author":"O\u2019Reilly","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.molmed.2019.02.001_bib0290","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/ijd.13308","article-title":"Inhibition of microRNA-21 induces apoptosis in dermal fibroblasts of patients with systemic sclerosis","volume":"55","author":"Jafarinejad-Farsangi","year":"2016","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0295","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1365-2133.2010.09861.x","article-title":"Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study","volume":"163","author":"Olesen","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0300","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.4049\/jimmunol.1403028","article-title":"miR-155 deficiency ameliorates autoimmune inflammation of systemic lupus erythematosus by targeting S1pr1 in Faslpr\/lpr mice","volume":"194","author":"Xin","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0305","doi-asserted-by":"crossref","first-page":"12970","DOI":"10.1038\/ncomms12970","article-title":"MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis","volume":"7","author":"Alivernini","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2019.02.001_bib0310","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13075-017-1331-z","article-title":"Mir-155 is overexpressed in systemic sclerosis fibroblasts and is required for NLRP3 inflammasome-mediated collagen synthesis during fibrosis","volume":"19","author":"Artlett","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.molmed.2019.02.001_bib0315","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13075-016-1054-6","article-title":"miR-155 in the progression of lung fibrosis in systemic sclerosis","volume":"18","author":"Christmann","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.molmed.2019.02.001_bib0320","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1073\/pnas.0811073106","article-title":"MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells","volume":"106","author":"Ceppi","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2019.02.001_bib0325","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/ni.1828","article-title":"Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the MicroRNA miR-21","volume":"11","author":"Sheedy","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0330","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ajpath.2012.09.007","article-title":"Toll-like receptor 4 signaling augments transforming growth factor-\u03b2 responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma","volume":"182","author":"Bhattacharyya","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0335","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/art.40163","article-title":"Association of microRNA-618 expression with altered frequency and activation of plasmacytoid dendritic cells in patients with systemic sclerosis","volume":"69","author":"Rossato","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0340","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.imlet.2017.09.001","article-title":"Toll like receptors in systemic sclerosis: an emerging target","volume":"195","author":"O\u2019Reilly","year":"2018","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.molmed.2019.02.001_bib0345","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11926-017-0630-3","article-title":"Innate immunity in systemic sclerosis","volume":"19","author":"Dowson","year":"2017","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.molmed.2019.02.001_bib0350","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/art.27443","article-title":"MicroRNA-29, a key regulator of collagen expression in systemic sclerosis","volume":"62","author":"Maurer","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2019.02.001_bib0355","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/exd.12245","article-title":"Hair miR-29a levels are decreased in patients with scleroderma","volume":"22","author":"Takemoto","year":"2013","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0360","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jdermsci.2010.11.007","article-title":"Circulating miR-29a levels in patients with scleroderma spectrum disorder","volume":"61","author":"Kawashita","year":"2011","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.molmed.2019.02.001_bib0365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115596","article-title":"MiR-29a reduces TIMP-1 production by dermal fibroblasts via targeting TGF-\u03b2 activated kinase 1 binding protein 1, implications for systemic sclerosis","volume":"9","author":"Ciechomska","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2019.02.001_bib0370","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1684\/ejd.2014.2384","article-title":"Down-regulation of microRNA-196a in the sera and involved skin of localized scleroderma patients","volume":"24","author":"Makino","year":"2014","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0375","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.4049\/jimmunol.1100876","article-title":"TGF-beta-mediated downregulation of microRNA-196a contributes to the constitutive upregulated type I collagen expression in scleroderma dermal fibroblasts","volume":"188","author":"Honda","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0380","first-page":"98","article-title":"Expression of Let-7 family microRNAs in skin correlates negatively with severity of pulmonary hypertension in patients with systemic scleroderma","volume":"8","author":"Izumiya","year":"2015","journal-title":"J. Cardiol. Heart Vasc."},{"key":"10.1016\/j.molmed.2019.02.001_bib0385","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.4049\/jimmunol.1200822","article-title":"The downregulation of microRNA let-7a contributes to the excessive expression of type I collagen in systemic and localized scleroderma","volume":"190","author":"Makino","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0390","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jdermsci.2017.12.017","article-title":"Regulatory mechanisms of collagen expression by interleukin-22 signaling in scleroderma fibroblasts","volume":"90","author":"Sawamura","year":"2018","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.molmed.2019.02.001_bib0395","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1093\/rheumatology\/ket254","article-title":"Alteration of circulating miRNAs in SSc: miR-30b regulates the expression of PDGF receptor \u03b2","volume":"52","author":"Suto","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.molmed.2019.02.001_bib0400","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.cell.2009.04.021","article-title":"Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model","volume":"137","author":"Kota","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2019.02.001_bib0405","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1101\/gr.116814.110","article-title":"What fraction of the human genome is functional?","volume":"21","author":"Ponting","year":"2011","journal-title":"Genome Res."},{"key":"10.1016\/j.molmed.2019.02.001_bib0410","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature11247","article-title":"An integrated encyclopedia of DNA elements in the human genome","volume":"489","author":"ENCODE Project Consortium","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2019.02.001_bib0415","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201846955","article-title":"Modulating the expression of long non-coding RNAs for functional studies","volume":"19","author":"Liu","year":"2018","journal-title":"EMBO Rep."},{"key":"10.1016\/j.molmed.2019.02.001_bib0420","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/exd.12900","article-title":"Long non-coding RNA TSIX is upregulated in scleroderma dermal fibroblasts and controls collagen mRNA stabilization","volume":"25","author":"Wang","year":"2016","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0425","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jid.2017.09.053","article-title":"Antisense long non-coding RNAs are deregulated in skin tissue of patients with systemic sclerosis","volume":"138","author":"Messemaker","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0430","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12943-019-0942-1","article-title":"Novel long noncoding RNA OTUD6B-AS1 indicates poor prognosis and inhibits clear cell renal cell carcinoma proliferation via the Wnt\/\u03b2-catenin signaling pathway","volume":"18","author":"Wang","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.molmed.2019.02.001_bib0435","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.3389\/fimmu.2018.02906","article-title":"Long non-coding RNAs are central regulators of the IL-1\u03b2-induced inflammatory response in normal and idiopathic pulmonary lung fibroblasts","volume":"9","author":"Hadjicharalambous","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0440","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.15252\/emmm.201303604","article-title":"MicroRNA mimicry blocks pulmonary fibrosis","volume":"6","author":"Montgomery","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.molmed.2019.02.001_bib0445","doi-asserted-by":"crossref","first-page":"875","DOI":"10.17219\/acem\/64334","article-title":"Systemic sclerosis sine scleroderma","volume":"26","author":"Kucharz","year":"2017","journal-title":"Adv. Clin. Exp. Med."},{"key":"10.1016\/j.molmed.2019.02.001_bib0450","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/art.10775","article-title":"Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement","volume":"48","author":"Steen","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2019.02.001_bib0455","doi-asserted-by":"crossref","first-page":"6910","DOI":"10.1158\/0008-5472.CAN-05-0530","article-title":"Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery","volume":"65","author":"Landen","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2019.02.001_bib0460","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1023\/A:1007504613351","article-title":"Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes","volume":"17","author":"Dokka","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.molmed.2019.02.001_bib0465","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1158\/1078-0432.CCR-12-2715","article-title":"Highly specific targeting of the TMPRSS2\/ERG fusion gene using liposomal nanovectors","volume":"18","author":"Shao","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2019.02.001_bib0470","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0475","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.hbpd.2018.09.013","article-title":"Histone deacetylase inhibitor suberoylanilide hydroxamic acid alleviates liver fibrosis by suppressing the transforming growth factor-beta1 signal pathway","volume":"17","author":"Wang","year":"2018","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"10.1016\/j.molmed.2019.02.001_bib0480","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/cen.13154","article-title":"A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin","volume":"86","author":"Nilubol","year":"2017","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0485","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s10157-016-1365-6","article-title":"Valproic acid attenuates renal fibrosis through the induction of autophagy","volume":"21","author":"Kawaoka","year":"2017","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0490","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-2141.2010.08395.x","article-title":"A randomized phase II trial of arginine butyrate with standard local therapy in refractory sickle cell leg ulcers","volume":"151","author":"McMahon","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-017-0053-3","article-title":"E2112: randomized phase III trial of endocrine therapy plus entinostat\/placebo in patients with hormone receptor-positive advanced breast cancer","volume":"4","author":"Yeruva","year":"2018","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.molmed.2019.02.001_bib0500","doi-asserted-by":"crossref","first-page":"7199","DOI":"10.1158\/1078-0432.CCR-17-1178","article-title":"Immunomodulation by entinostat in renal cell carcinoma patients receiving high-dose interleukin 2: a multicenter, single-arm, phase I\/II trial (NCI-CTEP#7870)","volume":"23","author":"Pili","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2019.02.001_bib0505","article-title":"Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2019.02.001_bib0510","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S1470-2045(11)70265-0","article-title":"Mocetinostat for relapsed classical Hodgkin\u2019s lymphoma: an open-label, single-arm, phase 2 trial","volume":"12","author":"Younes","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0515","doi-asserted-by":"crossref","first-page":"11482","DOI":"10.3390\/ijms160511482","article-title":"Anti-fibrotic effects of class I HDAC inhibitor, mocetinostat is associated with IL-6\/Stat3 signaling in ischemic heart failure","volume":"16","author":"Nural-Guvener","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2019.02.001_bib0520","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s12185-017-2286-1","article-title":"Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I\/II and pharmacokinetics study","volume":"106","author":"Maruyama","year":"2017","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0525","doi-asserted-by":"crossref","first-page":"48737","DOI":"10.18632\/oncotarget.17114","article-title":"The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis","volume":"8","author":"Conforti","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.molmed.2019.02.001_bib0530","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/onc.2009.445","article-title":"Regression of murine lung tumors by the let-7 microRNA","volume":"29","author":"Trang","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.molmed.2019.02.001_bib0535","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317692261","article-title":"Inhibition of microRNA-21 via locked nucleic acid-anti-miR suppressed metastatic features of colorectal cancer cells through modulation of programmed cell death 4","volume":"39","author":"Nedaeinia","year":"2017","journal-title":"Tumour Biol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0540","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1007\/s10875-013-9896-z","article-title":"MicroRNA-21 in scleroderma fibrosis and its function in TGF-\u03b2-regulated fibrosis-related genes expression","volume":"33","author":"Zhu","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0545","article-title":"Therapeutic delivery of microRNA-29b by cationic lipoplexes for lung cancer","volume":"2","author":"Wu","year":"2013","journal-title":"Molecular Therapy \u2212 Nucleic Acids"},{"key":"10.1016\/j.molmed.2019.02.001_bib0550","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.1167\/iovs.15-16558","article-title":"Suppression of type I collagen expression by miR-29b via PI3K, Akt, and Sp1 pathway, part II: an in vivo investigation","volume":"56","author":"Yu","year":"2015","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.molmed.2019.02.001_bib0555","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ymthe.2018.10.015","article-title":"LDR-induced miR-30a and miR-30b target the PAI-1 pathway to control adverse effects of NSCLC radiotherapy","volume":"27","author":"Park","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2019.02.001_bib0560","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1093\/rheumatology\/ket254","article-title":"Alteration of circulating miRNAs in SSc: miR-30b regulates the expression of PDGF receptor \u03b2","volume":"52","author":"Tanaka","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.molmed.2019.02.001_bib0565","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.193","article-title":"miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer","volume":"4","author":"Karaayvaz","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.molmed.2019.02.001_bib0570","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.4049\/jimmunol.1100591","article-title":"Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts","volume":"188","author":"Nakashima","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0575","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1530\/JOE-18-0287","article-title":"AAV8-mediated gene transfer of microRNA-132 improves beta-cell function in mice fed a high fat diet","volume":"240","author":"Mulder","year":"2018","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0580","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1158\/0008-5472.CAN-10-4645","article-title":"MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma","volume":"71","author":"Ibrahim","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2019.02.001_bib0585","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s10875-011-9647-y","article-title":"MicroRNA expression abnormalities in limited cutaneous scleroderma and diffuse cutaneous scleroderma","volume":"32","author":"Zhu","year":"2012","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0590","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.2147\/IJN.S82587","article-title":"Delivery of microRNA-146a with polyethylenimine nanoparticles inhibits renal fibrosis in vivo","volume":"10","author":"Morishita","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.molmed.2019.02.001_bib0595","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ajpath.2012.09.023","article-title":"miR-150 down-regulation contributes to the constitutive type I collagen overexpression in scleroderma dermal fibroblasts via the induction of integrin \u03b23","volume":"182","author":"Honda","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.molmed.2019.02.001_bib0600","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1093\/nar\/gkq160","article-title":"Efficient inhibition of miR-155 function in vivo by peptide nucleic acids","volume":"38","author":"Fabani","year":"2010","journal-title":"Nucl. Acids Res."},{"key":"10.1016\/j.molmed.2019.02.001_bib0605","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaut.2017.12.015","article-title":"Serum microRNA screening and functional studies reveal miR-483-5p as a potential driver of fibrosis in systemic sclerosis","volume":"89","author":"Chouri","year":"2018","journal-title":"J. Autoimmun."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147149141930022X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147149141930022X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T07:17:31Z","timestamp":1761463051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147149141930022X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":121,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S147149141930022X"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2019.02.001","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Epigenetic Modifications in Systemic Sclerosis: A Druggable Target","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2019.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}